Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gecacitinib hydrochloride + peginterferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Gecacitinib hydrochloride (SHR0302) is a potent and selective small-molecule inhibitor of Janus kinase 1 (JAK1). In this therapeutic combination, it is paired with peginterferon alfa-2b, a pegylated cytokine, for the treatment of polycythemia vera (PV). Gecacitinib works by modulating the JAK-STAT signaling pathway, which is a key driver in the pathogenesis of myeloproliferative neoplasms. Peginterferon alfa-2b exerts antiproliferative effects on the malignant hematopoietic clone and stimulates the immune system. This combination is currently being evaluated in clinical trials (such as NCT06344104) to determine if the dual inhibition of JAK signaling and cytokine-mediated growth control provides superior hematological and molecular responses in PV patients compared to standard therapies.
- Other names
- SHR0302 + peginterferon alfa-2b
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)JAK1 (Janus kinase 1)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on gecacitinib hydrochloride + peginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gecacitinib hydrochloride + peginterferon alfa-2b.